Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Non-Current Assets (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Non-Current Assets data on record, last reported at $44.4 million in Q3 2025.

  • For Q3 2025, Non-Current Assets changed 0.17% year-over-year to $44.4 million; the TTM value through Sep 2025 reached $175.4 million, down 41.81%, while the annual FY2024 figure was $43.9 million, 58.86% down from the prior year.
  • Non-Current Assets reached $44.4 million in Q3 2025 per TNXP's latest filing, up from $43.8 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $108.4 million in Q2 2023 and bottomed at $43.3 million in Q1 2025.
  • Average Non-Current Assets over 3 years is $71.7 million, with a median of $45.0 million recorded in 2024.
  • The widest YoY moves for Non-Current Assets: up 10.36% in 2024, down 58.86% in 2024.
  • A 3-year view of Non-Current Assets shows it stood at $106.7 million in 2023, then tumbled by 58.86% to $43.9 million in 2024, then increased by 1.1% to $44.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $44.4 million in Q3 2025, $43.8 million in Q2 2025, and $43.3 million in Q1 2025.